文献速递类风湿关节炎

巴瑞替尼治疗类风湿关节炎患者淋巴细胞亚群的特征与变化:一项整合分析

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
PubMed 文献 · Arthritis Rheumatol · 2018-10-22

该整合分析汇总了3项已完成的III期试验(RA-BEAM、RA-BUILD、RA-BEACON)和1项正在进行的长期延伸研究(RA-BEYOND)中2186例活动性类风湿关节炎患者的数据,分析巴瑞替尼治疗期间淋巴细胞亚群的变化及其与临床结局的关联。结果显示淋巴细胞亚群变化大多在正常参考范围内,且未与严重感染风险增加相关。

要点

  • 巴瑞替尼治疗第4周总淋巴细胞计数出现早期一过性升高,第12周恢复至基线水平。
  • T细胞及其亚群的变化在正常参考范围内,持续至第104周。
  • 巴瑞替尼4 mg/日组中观察到低NK细胞数量与治疗中出现感染之间可能存在适度关联,但未见于严重感染或带状疱疹。

核心结论

  • 巴瑞替尼治疗期间淋巴细胞亚群的变化大多在正常参考范围内,且未与严重感染风险增加相关。

研究设计与样本

  • 整合分析汇总了3项已完成的III期试验(RA-BEAM、RA-BUILD、RA-BEACON)和1项正在进行的长期延伸研究(RA-BEYOND)的数据,共纳入2186例活动性类风湿关节炎患者,比较安慰剂与巴瑞替尼治疗。

主要发现

  • 巴瑞替尼治疗第4周总淋巴细胞计数出现早期一过性升高,第12周恢复至基线水平。
  • 巴瑞替尼治疗至第104周期间,T细胞及其亚群的变化在正常参考范围内。
  • 巴瑞替尼治疗4周后B细胞及相关亚群增加,至104周治疗期间未见进一步增加。
  • 巴瑞替尼治疗4周后自然杀伤(NK)细胞暂时性升高,随后降至基线以下并随时间趋于稳定。
  • 巴瑞替尼治疗中淋巴细胞亚群变化与临床终点之间相关性较少,且多数相关性也见于安慰剂组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA). This study was undertaken to analyze changes in lymphocyte cell subsets during baricitinib treatment and to correlate these changes with clinical outcomes. METHODS: An integrated analysis was conducted by pooling data from 3 completed phase III trials comparing placebo with baricitinib treatment (RA-BEAM, RA-BUILD, and RA-BEACON) and 1 ongoing long-term extension study (RA-BEYOND) in patients with active RA (n = 2,186). RESULTS: Baricitinib treatment was associated with an early transient increase in total lymphocyte count at week 4, which returned to baseline by week 12. Transient changes within normal reference ranges in T cells and subsets were observed with baricitinib treatment, up to week 104. B cells and relevant subpopulations increased after 4 weeks of baricitinib treatment, with no further increases noted through 104 weeks of treatment. Natural killer (NK) cells temporarily increased after 4 weeks of baricitinib treatment, before decreasing below baseline levels and then stabilizing over time. With baricitinib treatment, few correlations were observed between changes in lymphocyte subsets and clinical end points, and most correlations were also observed within the placebo group. A modest potential association between low NK cell numbers and treatment-emergent infections was observed in the baricitinib 4 mg/day treatment group, but not for serious infections or herpes zoster. CONCLUSION: Overall, these findings demonstrate that changes in lymphocyte subsets were largely within normal reference ranges across the baricitinib phase III RA clinical program and were not associated with increased risk of serious infections.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tanaka Y, McInnes IB, Taylor PC, et al. Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis. Arthritis Rheumatol. 2018. PMID: 30058112. doi:10.1002/art.40680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。